Gedeon Richter: Cariprazine has a real chance of becoming the best-selling atypical antipsychotic drug

Dr. István Greiner, Director of Richter's R&D recounted the story of cariprazine's development. "It was not a one-off success; we have already brought 9 original medicines to the market since World War II. From 1998, we started to focus on the brain's dopamine 3 receptor, and the efforts eventually resulted in cariprazine. It was approved by FDA in 2015 for schizophrenia – first in the history of the Hungarian pharmaceutical industry – later in the EU, and its indications extended in the US first for the depressive episodes of bipolar depression I and in 2019 for the adjunctive treatment of patients with major depressive disorder. In a joint project with AbbVie, we are looking forward to the success of our molecule for the treatment of a psychiatric disease, which is currently in Phase I alongside 3 other candidates of our portfolio in Phase I trials."

BUDAPEST, Hungary, 10/04/2024 (informazione.it - comunicati stampa - salute e benessere)

 recounted the story of cariprazine's development.

 talked about the global positioning and availability of the drug. Kóczián added.  

Further information: Richter Gedeon

View original content: https://www.prnewswire.co.uk/news-releases/gedeon-richter-cariprazine-has-a-real-chance-of-becoming-the-best-selling-atypical-antipsychotic-drug-302111847.html